Nurix Therapeutics (NRIX) said Thursday that the US Food and Drug Administration has cleared an investigational new drug application for its oral IRAK4 degrader GS-6791/NX-0479, allowing for a phase 1 trial to start, which is expected to begin in Q2.
The company said it is to receive $5 million from Gilead Sciences (GILD) for the IND clearance and remains eligible for up to $420 million in potential future milestone payments as part of a 2019 collaboration agreement.
Nurix said GS-6791/NX-0479 has potential applications in rheumatology and dermatology, including rheumatoid arthritis and atopic dermatitis.
Under the terms of the 2019 collaboration agreement, Nurix and Gilead Sciences (GILD) are looking to discover, develop, and commercialize a pipeline of up to five therapies for cancer and other diseases, the company said.
Nurix shares were over 8% higher while Gilead shares were 0.2% higher in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。